Eckert & Ziegler makes its debut on the stock exchang
Radiopharmaceutical and medical technology specialist breaks into the SDAX
Eckert & Ziegler AG (ISIN DE0005659700) made its debut on 24th of March at the Frankfurt Stock Exchange in the SDAX index. The radiopharmaceutical and medical technology specialist is active worldwide and successfully listed its shares on the Prime Standard of the Frankfurt Stock Exchange in February 2023.The success story of Eckert & Ziegler
Eckert & Ziegler AG is a medical technology and radiopharmaceutical enterprise headquartered in Berlin that was established more than 100 years ago. The Group includes more than 100 subsidiaries with locations in 14 countries. The company is one of the world's leading providers of isotope technology for the medical, industrial, and research sectors. In addition, Eckert & Ziegler offers a broad range of medical devices, including implants for cancer treatment & minimally invasive surgery.Eckert & Ziegler reported sales of more than 450 million euros in 2022, an increase of around 30% compared to the previous year. In the first half of 2023, the company was able to increase its sales by 50% again. This growth is mainly driven by the demand for radiopharmaceuticals for cancer treatment and the introduction of innovative medical devices.
Due to the positive business development, Eckert & Ziegler further expands its production capacities. The company invested in a new production site for radiopharmaceuticals in South Carolina (U.S.) and acquired the French manufacturer of medical devices, Lemer Pax.
With the inclusion in the SDAX, Eckert & Ziegler AG is now part of the 70 largest German stock corporations listed on the Frankfurt Stock Exchange. This is a major success and important recognition for the entire company. The SDAX inclusion will further increase the visibility of the Eckert & Ziegler share and attract more investors.
Eckert & Ziegler share with potential
Analysts see further great potential in the Eckert & Ziegler share. The company benefits from the long-term megatrends of demographic change and increased demand for modern cancer therapies. In addition, Eckert & Ziegler is a pioneer in the field of radio-isotope production and is continuously expanding its technological lead.
The share of Eckert & Ziegler is traded on the Frankfurt Stock Exchange under the symbol EKF and the ISIN DE0005659700. The historical price development of the share as well as the current price can be found on the website of the Frankfurt Stock Exchange.
